Crystallization to obtain protein-ligand complexes for structure-aided drug design

被引:45
作者
Danley, Dennis E. [1 ]
机构
[1] Pfizer Inc, Pfizer Global Res & Dev, Dept Exploratory Med Sci, Groton, CT 06340 USA
来源
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY | 2006年 / 62卷
关键词
D O I
10.1107/S0907444906012601
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The use of X-ray crystallography to derive three-dimensional structures for structure-aided drug design ( SADD) is a common activity in drug discovery today. In this process, the structures of inhibitors or other ligands of interest complexed with their macromolecular target are solved and the structural information is used iteratively to design new molecules. The ability to form cocrystal complexes between a target protein and a ligand is essential to this process and therefore is of considerable interest to anyone practicing in this field. In the course of obtaining the necessary ligand-protein crystals, even with crystallization conditions well established for a protein of interest, obtaining co-structures with inhibitors either through cocrystallization or soaking is too often not successful. There are numerous potential reasons for this lack of success and this article outlines a number of possible factors that may be involved and discusses considerations that should be taken into account when designing successful experiments to obtain iterative costructures.
引用
收藏
页码:569 / 575
页数:7
相关论文
共 60 条
  • [21] PRELIMINARY-X-RAY DIFFRACTION STUDIES OF RECOMBINANT-19 KDA HUMAN FIBROBLAST COLLAGENASE
    HASSELL, AM
    ANDEREGG, RJ
    WEIGL, D
    MILBURN, MV
    BURKHART, W
    SMITH, GFH
    GRABER, P
    WELLS, TNC
    LUTHER, MA
    JORDAN, SR
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 1994, 236 (05) : 1410 - 1412
  • [22] Plasmodium falciparum glutathione S-transferase -: Structural and mechanistic studies on ligand binding and enzyme inhibition
    Hiller, N
    Fritz-Wolf, K
    Deponte, M
    Wende, W
    Zimmermann, H
    Becker, K
    [J]. PROTEIN SCIENCE, 2006, 15 (02) : 281 - 289
  • [23] Hirschler J, 1998, PROTEIN SCI, V7, P185
  • [24] A new strategy for improved secondary screening and lead optimization using high-resolution SPR characterization of compound-target interactions
    Huber, W
    [J]. JOURNAL OF MOLECULAR RECOGNITION, 2005, 18 (04) : 273 - 281
  • [25] The structure of an enzyme-product complex reveals the critical role of a terminal hydroxide nucleophile in the bacterial phosphotriesterase mechanism
    Jackson, C
    Kim, HK
    Carr, PD
    Liu, JW
    Ollis, DL
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2005, 1752 (01): : 56 - 64
  • [26] Protein-protein interaction at crystal contacts
    Janin, J
    Rodier, F
    [J]. PROTEINS-STRUCTURE FUNCTION AND GENETICS, 1995, 23 (04): : 580 - 587
  • [27] KUO LC, 1989, J BIOL CHEM, V264, P16246
  • [28] Lipinski CA, 2004, BIOTECH PHARM ASPECT, V1, P93
  • [29] Crystallographic identification of a noncompetitive inhibitor binding site on the hepatitis C virus NS5B RNA polymerase enzyme
    Love, RA
    Parge, HE
    Yu, X
    Hickey, MJ
    Diehl, W
    Gao, JJ
    Wriggers, H
    Ekker, A
    Wang, LA
    Thomson, JA
    Dragovich, PS
    Fuhrman, SA
    [J]. JOURNAL OF VIROLOGY, 2003, 77 (13) : 7575 - 7581
  • [30] CRYSTAL-STRUCTURES OF RECOMBINANT 19-KDA HUMAN FIBROBLAST COLLAGENASE COMPLEXED TO ITSELF
    LOVEJOY, B
    HASSELL, AM
    LUTHER, MA
    WEIGL, D
    JORDAN, SR
    [J]. BIOCHEMISTRY, 1994, 33 (27) : 8207 - 8217